Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LORENZO FALCHI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1417392937
CMS profile
6871596
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$82,669.90

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $55,955.75 19
Travel and Lodging $24,773.43 16
Food and Beverage $1,940.72 30

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LORENZO FALCHI

NPI 1417392937 · CMS profile ID 6871596

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417392937?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LORENZO FALCHI, NPI 1417392937, CMS profile ID 6871596. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417392937?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LORENZO FALCHI, NPI 1417392937, CMS profile ID 6871596. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417392937?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LORENZO FALCHI, NPI 1417392937, CMS profile ID 6871596, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1417392937?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $82,669.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
F. Hoffmann-La Roche AG $4,920.0006/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211537243 CMS
F. Hoffmann-La Roche AG $113.1406/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211537246 CMS
Gilead Sciences, Inc. $18.4906/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234544205 CMS
Gilead Sciences, Inc. $13.8706/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234578188 CMS
Genentech USA, Inc. $2,460.0003/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211537192 CMS
ABBVIE INC. $5,625.0002/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201834411 CMS
ABBVIE INC. $114.0202/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201834413 CMS
ABBVIE INC. $3,375.0002/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201834415 CMS
ABBVIE INC. $9,000.0002/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201834417 CMS
ABBVIE INC. $106.7402/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201834419 CMS
ABBVIE INC. $3,000.0002/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201834409 CMS
ABBVIE INC. $2,625.0001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201834407 CMS
ABBVIE INC. $750.0001/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201834405 CMS
Janssen Global Services, LLC $2,250.0001/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1173805403 CMS
AstraZeneca Pharmaceuticals LP $820.0001/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207306332 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $2,096.81 3
PY2022 $20,628.57 12
PY2023 $50,803.74 35
PY2024 $30,659.42 29
PY2025 $82,669.90 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,285.60 5
PY2025 Principal investigator $2,786,561.64 192
PY2024 Recipient $8,391.75 15
PY2024 Principal investigator $3,259,455.31 315
PY2023 Recipient $4,295.39 4
PY2023 Principal investigator $4,014,246.71 166
PY2022 Recipient $3,676.00 8
PY2022 Principal investigator $823,019.60 11
PY2021 Recipient $550.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

197 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient ABBVIE INC. $1,500.00 12/22/2025 Covered Recipient Physician A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202398084
Principal investigator 1 Genmab A/S $3,938.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932143
Principal investigator 1 Genmab A/S $1,227.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932152
Principal investigator 1 Genmab A/S $2,230.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932160
Principal investigator 1 Genmab A/S $3,938.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932188
Principal investigator 1 Genmab A/S $2,230.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932202
Principal investigator 1 Genmab A/S $3,938.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932211
Principal investigator 1 Genmab A/S $2,230.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932226
Principal investigator 1 Genmab A/S $3,490.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932234
Principal investigator 1 Genmab A/S $2,896.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932237
Principal investigator 1 Genmab A/S $3,042.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932245
Principal investigator 1 Genmab A/S $1,227.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932249
Principal investigator 1 Genmab A/S $2,230.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932265
Principal investigator 1 Genmab A/S $4,317.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932270
Principal investigator 1 Genmab A/S $2,230.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932290
Principal investigator 1 Genmab A/S $3,938.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932294
Principal investigator 1 Genmab A/S $3,938.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932306
Principal investigator 1 Genmab A/S $3,977.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932310
Principal investigator 1 Genmab A/S $2,986.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932318
Principal investigator 1 Genmab A/S $2,230.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932322
Principal investigator 1 Genmab A/S $1,227.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932334
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,338.26 12/10/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Modular Phase I and II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) No dispute reported 06/30/2026 1185546981
Principal investigator 1 ABBVIE INC. $6,142.40 12/04/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202528962
Principal investigator 1 Genmab A/S $2,230.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932148
Principal investigator 1 Genmab A/S $1,648.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932180
Principal investigator 1 Genmab A/S $2,230.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932194
Principal investigator 1 Genmab A/S $2,230.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932218
Principal investigator 1 Genmab A/S $1,477.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932222
Principal investigator 1 Genmab A/S $2,230.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932254
Principal investigator 1 Genmab A/S $2,230.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932277
Principal investigator 1 Genmab A/S $2,230.00 11/21/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932298
Principal investigator 1 ABBVIE INC. $9,408.25 11/04/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202520801
Principal investigator 1 BeOne Medicines USA, Inc. $426,000.00 10/29/2025 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy No dispute reported 06/30/2026 1190331301
Principal investigator 1 Genmab A/S $1,477.00 10/24/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932197
Principal investigator 1 Genmab A/S $2,230.00 10/24/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932229
Principal investigator 1 Genmab A/S $1,227.00 10/24/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932281
Principal investigator 1 Genmab A/S $1,476.00 10/24/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932286
Principal investigator 1 Genmab A/S $2,230.00 10/24/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932338
Principal investigator 1 ABBVIE INC. $20,060.10 10/09/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202515707
Principal investigator 1 Genmab A/S $1,227.00 10/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932156
Principal investigator 1 Genmab A/S $2,230.00 10/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932164
Principal investigator 1 Genmab A/S $2,230.00 10/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932176
Principal investigator 1 Genmab A/S $1,804.00 10/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932185
Principal investigator 1 Genmab A/S $1,227.00 10/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932330
Principal investigator 1 Genmab A/S $2,230.00 10/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932342
Principal investigator 1 BeOne Medicines USA, Inc. $426,000.00 09/16/2025 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy No dispute reported 06/30/2026 1190331299
Principal investigator 1 Genentech, Inc. $2,317.50 09/10/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624350
Principal investigator 1 ABBVIE INC. $36,545.04 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202507990
Principal investigator 1 Genmab A/S $2,230.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932023
Principal investigator 1 Genmab A/S $1,227.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932034
Principal investigator 1 Genmab A/S $2,230.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932046
Principal investigator 1 Genmab A/S $2,230.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932054
Principal investigator 1 Genmab A/S $1,648.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932098
Principal investigator 1 Genmab A/S $2,230.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932101
Principal investigator 1 Genmab A/S $1,227.00 08/20/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932136
Principal investigator 1 Genmab A/S $5,192.00 08/11/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932042
Principal investigator 1 ABBVIE INC. $12,698.01 08/05/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202501712
Principal investigator 1 Genmab A/S $2,230.00 07/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932081
Principal investigator 1 Genmab A/S $2,230.00 07/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932085
Principal investigator 1 Genmab A/S $2,230.00 07/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932106
Principal investigator 1 Genmab A/S $1,648.00 07/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932125
Recipient ABBVIE INC. $1,500.00 07/18/2025 Covered Recipient Physician A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202398080
Principal investigator 1 Genmab A/S $1,092.73 07/09/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932030
Principal investigator 1 Genmab A/S $1,639.10 07/09/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932057
Principal investigator 1 Genentech, Inc. $25,590.00 07/08/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211656345
Principal investigator 1 ABBVIE INC. $28,812.40 07/02/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202494455
Principal investigator 1 Genentech, Inc. $1,846.00 07/01/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624327
Principal investigator 1 Genmab A/S $3,042.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931893
Principal investigator 1 Genmab A/S $2,230.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931911
Principal investigator 1 Genmab A/S $1,227.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931920
Principal investigator 1 Genmab A/S $2,230.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931936
Principal investigator 1 Genmab A/S $2,230.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931961
Principal investigator 1 Genmab A/S $2,230.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931984
Principal investigator 1 Genmab A/S $2,230.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931999
Principal investigator 1 Genmab A/S $2,230.00 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932007
Principal investigator 1 Genentech, Inc. $2,090.50 06/24/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624277
Principal investigator 1 ABBVIE INC. $29,210.65 06/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202492323
Principal investigator 1 Genentech, Inc. $1,620.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624251
Principal investigator 1 Genentech, Inc. $1,617.00 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624256
Principal investigator 1 Genentech, Inc. $1,849.00 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624267
Principal investigator 1 Genentech, Inc. $1,563.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624275
Principal investigator 1 Genentech, Inc. $1,701.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624280
Principal investigator 1 Genentech, Inc. $1,463.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624284
Principal investigator 1 Genentech, Inc. $3,244.00 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624289
Principal investigator 1 Genentech, Inc. $1,800.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624293
Principal investigator 1 Genentech, Inc. $1,636.00 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624300
Principal investigator 1 Genentech, Inc. $1,780.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624304
Principal investigator 1 Genentech, Inc. $2,956.62 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624310
Principal investigator 1 Genentech, Inc. $1,881.50 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624315
Principal investigator 1 Genentech, Inc. $2,404.00 06/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624339
Principal investigator 1 Genentech, Inc. $2,108.50 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624246
Principal investigator 1 Genentech, Inc. $1,817.00 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624263
Principal investigator 1 Genentech, Inc. $1,791.50 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624270
Principal investigator 1 Genentech, Inc. $1,581.50 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624319
Principal investigator 1 Genentech, Inc. $1,910.50 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624323
Principal investigator 1 Genentech, Inc. $2,245.00 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624330
Principal investigator 1 Genentech, Inc. $1,781.50 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624335
Principal investigator 1 Genentech, Inc. $2,012.50 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624343
Principal investigator 1 Genentech, Inc. $1,646.00 06/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624347
Principal investigator 1 Genmab A/S $222.00 06/04/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931952
Principal investigator 1 Genmab A/S $2,356.00 06/04/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931976
Principal investigator 1 Genmab A/S $1,716.00 06/04/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931996
Principal investigator 1 Genmab A/S $286.00 06/04/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932004
Principal investigator 1 ABBVIE INC. $23,223.91 06/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202489867
Principal investigator 1 Genentech, Inc. $15,675.12 06/03/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
CD19 CD28 EIH No dispute reported 06/30/2026 1211656340
Principal investigator 1 Genentech, Inc. $3,620.00 05/27/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
glofitamab ctDNA study No dispute reported 06/30/2026 1211656385
Principal investigator 1 Genentech, Inc. $52,664.20 05/21/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
CD19 CD28 EIH No dispute reported 06/30/2026 1211656334
Principal investigator 1 Genentech, Inc. $59,200.55 05/21/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211656337
Principal investigator 1 Genmab A/S $1,227.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931900
Principal investigator 1 Genmab A/S $2,230.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931908
Principal investigator 1 Genmab A/S $1,477.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931915
Principal investigator 1 Genmab A/S $2,230.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931924
Principal investigator 1 Genmab A/S $2,230.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931927
Principal investigator 1 Genmab A/S $1,227.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931944
Principal investigator 1 Genmab A/S $2,230.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931956
Principal investigator 1 Genmab A/S $1,227.00 05/19/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931972
Principal investigator 1 Genentech, Inc. $744.50 05/08/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624242
Principal investigator 1 ABBVIE INC. $30,841.63 05/07/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202483031
Principal investigator 1 BeOne Medicines USA, Inc. $426,000.00 05/06/2025 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy No dispute reported 06/30/2026 1190331297
Recipient ABBVIE INC. $750.00 04/29/2025 Covered Recipient Physician A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202398076
Recipient F. Hoffmann-La Roche AG $407.86 04/28/2025 Covered Recipient Physician Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211537445
Principal investigator 1 Genentech, Inc. $3,272.00 04/28/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
glofitamab ctDNA study No dispute reported 06/30/2026 1211656390
Recipient F. Hoffmann-La Roche AG $127.74 04/25/2025 Covered Recipient Physician Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211537440
Principal investigator 1 Genmab A/S $1,477.00 04/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931965
Principal investigator 1 Genmab A/S $2,230.00 04/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931980
Principal investigator 1 Genmab A/S $2,230.00 04/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931992
Principal investigator 1 Genmab A/S $2,230.00 04/23/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235932019
Principal investigator 1 ABBVIE INC. $7,490.75 04/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202477211
Principal investigator 1 Genentech, Inc. $15,675.12 04/09/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH MEMORIAL CTR INDUSTRIAL AFFAIRS
CD19 CD28 EIH No dispute reported 06/30/2026 1211656342
Principal investigator 1 ABBVIE INC. $34,124.48 04/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202473923
Principal investigator 1 Genmab A/S $2,230.00 04/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931904
Principal investigator 1 Genmab A/S $2,230.00 04/02/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931988
Principal investigator 1 BeOne Medicines USA, Inc. $403,839.00 03/25/2025 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy No dispute reported 06/30/2026 1190338354
Principal investigator 1 ABBVIE INC. $30,607.02 03/07/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202459190
Principal investigator 1 Genmab A/S $4,678.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931274
Principal investigator 1 Genmab A/S $1,648.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931290
Principal investigator 1 Genmab A/S $1,648.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931340
Principal investigator 1 Genmab A/S $4,216.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931347
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931354
Principal investigator 1 Genmab A/S $1,227.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931393
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931472
Principal investigator 1 Genmab A/S $1,648.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931487
Principal investigator 1 Genmab A/S $1,648.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931502
Principal investigator 1 Genmab A/S $4,725.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931510
Principal investigator 1 Genmab A/S $4,713.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931534
Principal investigator 1 Genmab A/S $5,377.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931542
Principal investigator 1 Genmab A/S $8,023.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931553
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931557
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931567
Principal investigator 1 Genmab A/S $4,014.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931578
Principal investigator 1 Genmab A/S $4,678.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931620
Principal investigator 1 Genmab A/S $6,966.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931637
Principal investigator 1 Genmab A/S $4,014.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931665
Principal investigator 1 Genmab A/S $4,014.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931668
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931672
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931679
Principal investigator 1 Genmab A/S $7,073.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931683
Principal investigator 1 Genmab A/S $1,227.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931707
Principal investigator 1 Genmab A/S $2,230.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931736
Principal investigator 1 Genmab A/S $1,477.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931767
Principal investigator 1 Genmab A/S $1,648.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931791
Principal investigator 1 Genmab A/S $6,982.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931823
Principal investigator 1 Genmab A/S $4,915.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931839
Principal investigator 1 Genmab A/S $2,183.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931867
Principal investigator 1 Genmab A/S $4,014.00 03/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931871
Principal investigator 1 Genentech, Inc. $1,336.50 02/19/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
glofitamab ctDNA study No dispute reported 06/30/2026 1211656228
Principal investigator 1 Genentech, Inc. $4,009.50 02/19/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
glofitamab ctDNA study No dispute reported 06/30/2026 1211656232
Principal investigator 1 ABBVIE INC. $13,628.87 02/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202451281
Principal investigator 1 ABBVIE INC. $10,882.90 02/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202451300
Principal investigator 1 Genentech, Inc. $1,688.00 02/12/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624235
Principal investigator 1 Genentech, Inc. $1,699.50 02/12/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
MOSUNETUZUMAB FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA No dispute reported 06/30/2026 1211624239
Principal investigator 1 ABBVIE INC. $33,466.46 02/06/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202448474
Principal investigator 1 ABBVIE INC. $64,787.48 02/06/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202448478
Principal investigator 1 Genmab A/S $1,144.00 02/05/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931328
Principal investigator 1 Genmab A/S $333.00 02/05/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931358
Principal investigator 1 Genmab A/S $4,712.00 02/05/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931480
Principal investigator 1 Genmab A/S $9,206.00 02/05/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931498
Principal investigator 1 Genmab A/S $2,230.00 02/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931404
Principal investigator 1 Genmab A/S $2,230.00 02/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931506
Principal investigator 1 Genmab A/S $2,230.00 02/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931574
Principal investigator 1 Genmab A/S $2,230.00 02/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931613
Principal investigator 1 Genmab A/S $1,577.00 02/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931655
Principal investigator 1 Genmab A/S $2,230.00 02/03/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931781
Principal investigator 1 Genentech, Inc. $3,115.75 01/28/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211656219
Principal investigator 1 Genentech, Inc. $30,275.25 01/21/2025 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL No dispute reported 06/30/2026 1211656214
Principal investigator 1 ABBVIE INC. $4,286.25 01/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202439360
Principal investigator 1 ABBVIE INC. $5,737.50 01/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202439363
Principal investigator 1 ABBVIE INC. $4,482.00 01/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202439374
Principal investigator 1 ABBVIE INC. $63,806.34 01/10/2025 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202437944
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931494
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931633
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931661
Principal investigator 1 Genmab A/S $3,042.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931710
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931714
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931729
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931788
Principal investigator 1 Genmab A/S $2,230.00 01/06/2025 Non-covered Recipient Entity
MEMORIAL SLOANKETTERING CANCER CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235931827